Efficacy and safety of infliximab and adalimumab in inflammatory bowel disease patients.

Mahmoud E Kamal Rehab H WeridaMahasen A RadwanSafaa R AskarGamal A OmranMarwa A El-MohamdyRadwa S Hagag

Published in: Inflammopharmacology (2024)

This study is registered on ClinicalTrials.gov under the identifier NCT05291039. (You can access the study at https://clinicaltrials.gov/study/NCT05291039 (First Posted: March 22, 2022).

Keyphrases

end stage renal disease
rheumatoid arthritis
chronic kidney disease
ejection fraction
systemic lupus erythematosus
prognostic factors
patient reported
hidradenitis suppurativa